{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000057","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-08-03T20:15:23+00:00","discovered_at":"2026-08-03T20:16:00.503298+00:00","generated_at":"2026-08-03T20:16:05.363991+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma regains NYSE American listing compliance after $13.6M offering","bullets":["Received NYSE American letter confirming compliance with continued listing standards; .BC indicator to be removed.","Resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.","Compliance achieved after July 2026 underwritten public offering: 17.85M shares + pre-funded warrants, net proceeds ~$13.6M.","Potential additional $34M gross proceeds from milestone warrants if fully exercised.","Company believes stockholders' equity now exceeds $4M minimum requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000057","json":"https://secwatch.observer/filing/0001837607-26-000057.json","markdown":"https://secwatch.observer/filing/0001837607-26-000057.md","text":"https://secwatch.observer/filing/0001837607-26-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/0001837607-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/aeon-20260803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:16:05.363991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}